Alois Alzheimer first described his eponymous disease a century ago, but there are still no effective treatments. For World Alzheimer’s Day, Professor Bart de Strooper, Director of the UK Dementia Research Institute, asks why that is, and tells us how that might all be about to change.
Professor Bart de Strooper
In the early 1900s, a German neurologist called Alois Alzheimer became obsessed with studying an Asylum patient in her 50s, who had started to show unusual behavioural changes, including short-term memory loss. After her death he examined her brain and discovered structures known as amyloid plaques and neurofibrillary tangles – the hallmarks of what became known as Alzheimer’s disease. So why, when we’ve known about the disease for so long, are there still no treatments? Read more
Just how useful is it to get access to a pharmaceutical company compound? Back in 2012 Dr Richard Mead of the University of Sheffield was one of 15 academic project leaders funded by the MRC to research an alternative use for a compound no longer being developed by AstraZeneca. As we launch the next round of the MRC-Industry Asset Sharing Initiative he tells us how the collaboration has brought together the best of both worlds.
Copyright: Richard Mead
I’m no stranger to the pharmaceutical industry. I spent three years in drug development at Celltech in the early 2000s. But even with my experience, it’s still amazing to be reminded of the resources that pharmaceutical companies have at their fingertips. It sounds obvious, but their access to unique compounds, and their ability to make them, is impressive. Read more
Jennifer Lawson is the Trials Manager for the recently launched Deep and Frequent Phenotyping study looking to do the most in-depth research ever conducted to find out how Alzheimer’s disease develops. She is part of Professor Simon Lovestone’s Translational Neuroscience and Dementia Research group at the University of Oxford.
Career in brief
- Psychology BSc
- Worked at the Oxford Mental Health Trust as a Research Coordinator
- Part time Cognitive Neuroscience MSc whilst working full time at the Trust
- Managed the feasibility study that has led to this Deep and Frequent Phenotyping study
My career path has been slightly unusual. Like many of my peers studying psychology, I planned to become a clinical psychologist. So I went to gain experience working in Oxford Health NHS Foundation Trust, assisting with clinical trials and other research studies.